OUD

Background: People who have problems with using opioids or other drugs and inject them have shorter lives than most people. Liver diseases, especially, contribute to this. Checking liver stiffness might help find liver problems early. This...

Abstract Objective We evaluated the impact of a telemedicine bridge clinic on treatment outcomes and cost for patients with opioid use disorder. Telemedicine bridge clinics deliver low-barrier rapid assessment of patients with opioid use...

Abstract Objective: Opioid use disorder (OUD) in the United States has surged, with an estimated 2.5 million needing treatment. The aim of this article is to provide a clinical overview of the key pharmacological and behavioral treatments...

Abstract Background The prevalence and associated overdose death rates from opioid use disorder (OUD) have dramatically increased in the last decade. Despite more available treatments than 20 years ago, treatment access and high...

Background People with opioid use disorder (OUD) are frequently in contact with the court system and have markedly higher rates of fatal opioid overdose. Opioid intervention courts (OIC) were developed to address increasing rates of opioid...

Authors: Mohammad Jalali, PhD
Harvard University
Wayne Wakeland, PhD
Portland State University Abstract:
The opioid crisis is one of the most pressing public health issues in the U.S. today. Opioid overdoses are the proverbial “tip of the...

Abstract Importance Medication for opioid use disorder (MOUD) (eg, buprenorphine and naltrexone) can be offered in primary care, but barriers to implementation exist. Objective To evaluate an implementation intervention over 2 years to...

Discussion Despite guidelines recommending MOUD, approximately 1 in 5 adults with past-year OUD received any MOUD. Furthermore, some groups were substantially less likely to receive MOUD, in particular Black adults, women, those unemployed...

For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...